Thalidomide in cancer medicine

被引：102

作者：

Eleutherakis-Papaiakovou, V ^{[1
]}

Bamias, A ^{[1
]}

Dimopoulos, MA ^{[1
]}

机构：

[1] Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece

来源：

ANNALS OF ONCOLOGY | 2004年 / 15卷 / 08期

关键词：

angiogenesis; antiangiogenic therapy; cancer; myeloma; thalidomide;

D O I：

10.1093/annonc/mdh300

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Thalidomide, an oral agent with antiangiogenic and immunomodulatory properties, is being investigated extensively in the management of advanced cancer. Multiple studies with large numbers of patients have confirmed that this drug has significant activity in multiple myeloma. Some patients with myelofibrosis or myeodysplatic syndromes may reduce their need for transfusions after thalidomide treatment. The activity of thalidomide in solid tumors is less prominent. Studies in Kaposi's sarcoma, malignant melanoma, renal cell carcinoma and prostate cancer appear more promising especially when thalidomide is combined with biological agents or with chemotherapy. Limited activity was demonstrated in patients with glioma, while thalidomide appears to be inactive in patients with head and neck cancer, breast or ovarian cancer.

引用

页码：1151 / 1160

页数：10

共 83 条

[1]

Thalidomide for resistant and relapsing myeloma [J].

Alexanian, R ;

Weber, D .

SEMINARS IN HEMATOLOGY, 2000, 37 (01) :22-25

[2]

Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy [J].

Alexanian, R ;

Weber, D ;

Giralt, S ;

Delasalle, K .

ANNALS OF ONCOLOGY, 2002, 13 (07) :1116-1119

[3]

AMATO RJ, 2003, P AN M AM SOC CLIN, V22, pA387

[4]

Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide [J].

Ando, L ;

Price, DK ;

Dahut, WL ;

Cox, MC ;

Reed, E ;

Figg, WD .

CANCER BIOLOGY & THERAPY, 2002, 1 (06) :669-673

[5]

Badros AZ, 2003, BLOOD, V102, p684A

[6]

Phase II evaluation of thalidomide in patients with metastatic breast cancer [J].

Baidas, SM ;

Winer, EP ;

Fleming, GF ;

Harris, L ;

Pluda, JM ;

Crawford, JG ;

Yamauchi, H ;

Isaacs, C ;

Hanfelt, J ;

Tefft, M ;

Flockhart, D ;

Johnson, MD ;

Hawkins, MJ ;

Lippman, ME ;

Hayes, DF .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (14) :2710-2717

[7]

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients [J].

Barlogie, B ;

Desikan, R ;

Eddlemon, P ;

Spencer, T ;

Zeldis, J ;

Munshi, N ;

Badros, A ;

Zangari, M ;

Anaissie, E ;

Epstein, J ;

Shaughnessy, J ;

Ayers, D ;

Spoon, D ;

Tricot, G .

BLOOD, 2001, 98 (02) :492-494

[8]

Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia [J].

Barosi, G ;

Grossi, A ;

Comotti, B ;

Musto, P ;

Gamba, G ;

Marchetti, M .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (01) :78-83

[9]

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent [J].

Bauer, KS ;

Dixon, SC ;

Figg, WD .

BIOCHEMICAL PHARMACOLOGY, 1998, 55 (11) :1827-1834

[10]

Thalidomide in patients with cachexia due to terminal cancer: Preliminary report [J].

Bruera, E ;

Neumann, CM ;

Pituskin, E ;

Calder, K ;

Ball, G ;

Hanson, J .

ANNALS OF ONCOLOGY, 1999, 10 (07) :857-859

← 1 2 3 4 5 6 7 8 9 →